Mark Andrews
Corporate Officer/Principal presso PharmaVentures Ltd.
Profilo
Mark Andrews is currently the Managing Director at PharmaVentures Ltd.
He previously worked as a Director at Opsona Therapeutics Ltd.
and as an Investment Manager at DEWB AG (Venture Capital).
From 2007 to 2015, he was a Principal at Inventages Venture Capital Investment, Inc. He also worked as a Principal at Biotech Venture Management LLC.
Dr. Andrews received his undergraduate degree from the University of Birmingham in 1992 and his graduate degree from De Montfort University in 1993.
Posizioni attive di Mark Andrews
Società | Posizione | Inizio |
---|---|---|
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Precedenti posizioni note di Mark Andrews
Società | Posizione | Fine |
---|---|---|
Inventages Venture Capital Investment, Inc
Inventages Venture Capital Investment, Inc Investment ManagersFinance Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London. | Corporate Officer/Principal | 31/03/2015 |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | Private Equity Investor | 30/12/2006 |
Biotech Venture Management LLC | Corporate Officer/Principal | - |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Director/Board Member | - |
Formazione di Mark Andrews
University of Birmingham | Undergraduate Degree |
De Montfort University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Finance |
Inventages Venture Capital Investment, Inc
Inventages Venture Capital Investment, Inc Investment ManagersFinance Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London. | Finance |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | Finance |
Biotech Venture Management LLC | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Mark Andrews